NEW YORK (TheStreet) -- GW Pharmaceuticals (GWPH) stock is soaring, up 31.1% to $60.37 in trading on Tuesday.
The increase follows coverage initiation on the cannabis prescription drug company's stock with an "overweight" rating by analysts at Morgan Stanley (MS). The firm set a $103 price target on the company's shares.
Must Read: Warren Buffett's 10 Favorite Stocks
SELL NOW: If you own any of the 900 stocks that TheStreet Quant Ratings has identified as a 'Sell'...you could potentially lose EVERYTHING in the next 6-12 months. Learn more.
Analysts see the company's cannabis based epilepsy treatment drug, Epidiolex, as having "strong potential, with the epilepsy program driving valuation."
"While small and still anecdotal, there is a consistently strong and building set of data (case cohort and controlled) which highlight the positive impact of Cannabidiol on refractory epilepsy pts," the firm said.